Dubois, Bruno
von Arnim, Christine A. F.
Burnie, Nerida
Bozeat, Sasha
Cummings, Jeffrey
Funding for this research was provided by:
Roche Diagnostics International Ltd, Rotkreuz, Switzerland
Article History
Received: 4 January 2023
Accepted: 25 September 2023
First Online: 13 October 2023
Declarations
:
: Not applicable.
: Not applicable.
: B.D. is a consultant for ABScience, Biogen, Eli Lilly, MedAvante, and Qynapse, and has received research grants for his institution from AVID, Fondation Merck-Avenir, Fondation de Recherche sur Alzheimer (FRA), Pfizer, and Roche. C.A.F.v.A. has received: honoraria for serving on the scientific advisory board of Biogen, Dr. Willmar Schwabe GmbH & Co. KG, Novo Nordisk, and Roche; funding for travel and speaker honoraria from Biogen, Dr. Willmar Schwabe GmbH & Co. KG, Medical Tribune Verlagsgesellschaft mbH, Novartis, and Roche Diagnostics AG; and research support from Roche Diagnostics AG. N.B. has no competing interests to declare. S.B. is a full-time employee of F. Hoffmann-La Roche AG. J.C. has provided consultation to Acadia, Alkahest, AlphaCognition, AriBio, Biogen, Cortexyme, Diadem, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, Grifols, Janssen, Karuna, Lilly, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Ono, Otsuka, PRODEO, Prothena, ReMYND, Resverlogix, Roche, Signant Health, Suven, and United Neuroscience pharmaceutical, assessment, and investment companies. J.C. is supported by: the Alzheimer’s Disease Drug Discovery Foundation (ADDF); the Joy Chambers-Grundy Endowment; NIA grant P20AG068053; NIA grant R01AG053798; NIA grant R35AG71476; NIGMS grant P20GM109025; NINDS grant U01NS093334; and Ted and Maria Quirk Endowment for the Pam Quirk Brain Health, and Biomarker Laboratory.